Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation

NCT06319391 | Active Not Recruiting

• 1 other identifier: JSZ007
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Tacrolimus is the most commonly used immunosuppressant for preventing and treating rejection after liver transplantation. However, its treatment window is narrow, the pharmacokinetic individual differences are large, routine dose according to body weight, sometimes low dose will cause graft rejection of patients, or high dose will lead to infection and liver and kidney toxicity and other adverse reactions. Moreover, the conventional drug testing can not fully reflect the efficacy of tacrolimus, and there are shortcomings of lag, experience and passivity. FK506 is metabolized primarily by cytochrome P450 member 3A5 in the liver and intestines. CYP3A5\*3 is the most important factor determining the expression level of CYP3A5. This mutation can cause variable shear and produce unstable protein, so that patients carrying CYP3A5\*3/\*3 gene do not express CYP3A5. Acute kidney injury is a common and important complication after liver transplantation. Despite recent advances in organ preservation, surgical techniques, and immunosuppressive protocols, the incidence of AKI after orthotopic liver transplantation remains high. AKI has a significant impact on both short - and long-term prognosis of orthotopic liver transplantation recipients. Studies have shown that orthotopic liver transplantation recipients with AKI have significantly higher mortality rates in hospital, at 28 days and at 1 year after surgery than those without AKI. In this study, the relationship between donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration was investigated, and the effect of donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration on acute kidney injury after liver transplantation was investigated. To provide guidance for individual administration of gene-directed tacrolimus in patients, and provide basis for prevention and reduction of postoperative acute kidney injury in liver transplantation patients.

Conditions

Complete and Accurate Statistical Data of 60 Patients; CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately; Postoperative Tacrolimus Concentrations Were Accurately Recorded in 60 Patients; According to the Diagnosis and Grading Criteria of Acute Kidney Injury, the Cases and Grading of Postoperative Acute Kidney Injury in 60 Patients Were Counted; Scientific and Rigorous Statistical Analysis of Data

Keywords

CYP3A5; gene polymorphism; tacrolimus; acute kidney injury

Outcome Measures

Primary Outcomes (2)

• Fk506

  Tacrolimus concentration

  1-28 days postoperatively

• Scr

  Reflects indicators of kidney function

  1-28 days postoperatively

Study Arms (4)

donor/acceptor expression group

Other: CYP3A5*1*、CYP3A5*1*3

donor expression/acceptor non-expression

donor non-expression/acceptor expression

donor/acceptor non-expression group

Other: CYP3A5*3*3

Interventions

CYP3A5*1*、CYP3A5*1*3 OTHER

2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system. After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.

donor/acceptor expression group

CYP3A5*3*3 OTHER

2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system.After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.

donor/acceptor non-expression group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

60 patients receiving liver transplantation at the center of Qianfoshan Hospital in 2022.01-2023.06

You may qualify if:

• Patients undergoing orthotopic liver transplantation in our center.
• The postoperative immunosuppression regimen was tacrolimus、methylprednisolone and balipremumab for injection in all cases,and no drugs that interacted with tacrolimus were used.
• The postoperative follow-up time was greater than 6 months and no serious rejection occurred during the follow-up period.

You may not qualify if:

• Combined organ transplantation.
• liver transplant patients on other immunosuppressive regimens.
• Preoperative CKD or need RRT.
• Preoperative serum creatinine (SCr) \> 133 mol/L.
• Loss of follow-ups.

Sponsors & Collaborators

• Ziqiang Li: lead

Study Sites (1)

The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)

Jinan, Shandong, 250013, China

Location

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• Liziqiang Liziqiang, Doctor

  Party

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: March 5, 2024
• First Posted: March 20, 2024
• Study Start: April 1, 2023
• Primary Completion: May 1, 2024
• Study Completion: October 1, 2025
• Last Updated: March 20, 2024

Record last verified: 2024-03

Locations

CN (1)